Vinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo SliderVinaora Nivo Slider




DI.V.A.L. can provide IN VIVO DRUG EFFICACY EVALUATIONIn particular, we can develop the following tumor animal models:

  • Subcutaneous xenograft tumor models, valuable for predicting cytotoxicity of cancer drugs and widely used in efficacy studies for its simplicity and easy access to tumor measurement. We offer a large range of subcutaneous xenograft tumor models derived from human cancer cell lines.
  • Bone-marrow tumor models
  • Orthotopic tumor models, to predict the drug efficacy with high clinical relevance and low false positive rate. We have established a variety of orthotopic tumor models like pancreatic orthotopic tumor models.Tumor volume, time to progression or doubling, tumoral dissemination (blood, bone marrow, spleen,…) and metastasis can also be tracked by in vivo bioluminescence imaging if the cancer cells are labeled with luciferase.

DI.V.A.L. provides a complete range of transgenic services for the production of genetically modified mice to be used as models to understand human diseases, such as generation of transgenic mice by pronuclear injection and gene targeting to produce knock-in and knock-out models starting from electroporation to injection of mutated ES cells. DI.V.A.L. is also able to derivate and establish in culture new embryonic cell lines. Recently we also started to set up the method for knock-out and knock-in mouse models by the use of CRISPR-Cas9 system, which is a highly efficient, quick and less expensive technology for generating mice with targeted mutations.

We are experts in culturing mouse embrionyc stem (ES) cellstargeting constructs and viral (AAV, SV40-based) vectors

We can also provide customized disease mouse models (nervous system, cardiovascular and immunohaematological diseases, cancer research) validated by flow cytometry analysis of peripheral and bone marrow blood.

Non oncological models:

  • Endometriosis
  • Chron disease
  • Experimental Autoimmune Encephalomyelitis (EAE)
  • Dry eye syndrome
  • Type 1 diabetes
  • Sepsis
Oncological models:
  • Acute leukemia
  • Colorectal cancer (liver metastases and orthotopic model)
  • Bladder cancer
  • Hepatocarcinoma
  • Endometrial cancer
  • Pancreatic cancer

Transgenic models:
  • Pancreatic Adenocarcinoma Model (triple transgenic). This model will be used in the projects IPERNANO and RAPIDPHARMA
  • hERG channel Iperexpression Model ("Characterization of hERG1 channel role in mouse colorectal carcinogenesis" Fiore A. et al 2013)
  • LHR Iperexpression in endometrium Model
  • hERG 1b KO mice Model (Role of the Ether-à-go-go-Related Gene 1B Isoform in hematopoiesis Blood (ASH Annual Meeting Abstracts, Nov 2012; 120: 1222)